A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens

Vaccine

Volumn 24, Issue 10, 2006, Pages 1680-1686

  Singh, Manmohan ^a   Ugozzoli, Mildred ^a   Kazzaz, Jina ^a   Chesko, James ^a   Soenawan, Elawati ^a   Mannucci, Donatella ^b   Titta, Francesca ^b   Contorni, Mario ^b   Volpini, Gianfranco ^b   Guidice, Giuseppe Del ^b   O'Hagan, Derek T ^a  

^a Vaccines Research   (United States)

^b CHIRON VACCINES   (Italy)

Author keywords

Alum; CAP; L Tyrosine; MF59 emulsion; PLG microparticles

Indexed keywords

ALUMINUM POTASSIUM SULFATE; ANTIGEN; BACTERIAL VACCINE; CALCIUM PHOSPHATE; DIPHTHERIA VACCINE; HEPATITIS B SURFACE ANTIGEN; IMMUNOLOGICAL ADJUVANT; MENINGOCOCCUS VACCINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; POLYGLACTIN; TETANUS TOXOID; TYROSINE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; DRUG RELEASE; DRUG SCREENING; EMULSION; IMMUNOGENICITY; LOW DRUG DOSE; MOUSE; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL; SUSPENSION;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; CALCIUM PHOSPHATES; DIPHTHERIA TOXOID; HEPATITIS B SURFACE ANTIGENS; IMMUNIZATION; LACTIC ACID; MENINGOCOCCAL VACCINES; MICE; MICE, INBRED BALB C; PARTICLE SIZE; POLYGLYCOLIC ACID; POLYMERS; POLYSORBATES; SQUALENE; TETANUS TOXOID; VACCINES;

EID: 32544434933     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.09.046     Document Type: Article

References (33)

1. A. Glenny, C. Pope, H. Waddington, and U. Falacce The antigenic value of toxoid precipitated by potassium alum J Pathol Bacteriol 29 1926 31 40
2. E.B. Lindblad Aluminium adjuvants - in retrospect and prospect Vaccine 22 27-28 2004 3658 3668
3. R.K. Gupta, E.H. Relyveld, E.B. Lindblad, B. Bizzini, S. Ben-Efraim, and C.K. Gupta Adjuvants - a balance between toxicity and adjuvanticity Vaccine 11 3 1993 293 306
4. R.K. Gupta, and G.R. Siber Adjuvants for human vaccines - current status, problems and future prospects Vaccine 13 14 1995 1263 1276
5. C.J. Clements, and E. Griffiths The global impact of vaccines containing aluminium adjuvants Vaccine 20 Suppl. 3 2002 S24 S33
6. B. Trollfors, E. Bergfors, A. Inerot, D.T. O'Hagan, M. Singh, and H. Xie Vaccine related itching nodules and hypersensitivity to aluminium Vaccine 23 8 2005 975 976
7. T. Jefferson, M. Rudin, and C. Di Pietrantonj Adverse events after immunisation with aluminium-containing DTP vaccines: systematic review of the evidence Lancet Infect Dis 4 2 2004 84 90
8. A. Podda, and G. Del Giudice MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile Expert Rev Vaccines 2 2 2003 197 203
9. P. Traquina, M. Morandi, M. Contorni, and G. Van Nest MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates J Infect Dis 174 6 1996 1168 1175
10. D.M. Granoff, Y.E. McHugh, H.V. Raff, A.S. Mokatrin, and G.A. Van Nest MF59 adjuvant enhances antibody responses of infant baboons immunized with Haemophilus influenzae type b and Neisseria meningitidis group C oligosaccharide-CRM197 conjugate vaccine Infect Immun 65 5 1997 1710 1715
11. H. Okada, and H. Toguchi Biodegradable microspheres in drug delivery 12 1 1995 1 99
12. R. Shahin, M. Leef, J. Eldridge, M. Hudson, and R. Gilley Adjuvanticity and protective immunity elicited by Bordetella pertussis antigens encapsulated in poly(dl-lactide-co-glycolide) microspheres Infect Immun 63 4 1995 1195 1200
13. P.A. Marx, R.W. Compans, A. Gettie, J.K. Staas, R.M. Gilley, and M.J. Mulligan Protection against vaginal SIV transmission with microencapsulated vaccine Science 260 5112 1993 1323 1327
14. J. Tseng, J.L. Komisar, R.N. Trout, R.E. Hunt, J.Y. Chen, and A.J. Johnson Humoral immunity to aerosolized staphylococcal enterotoxin B (SEB), a superantigen, in monkeys vaccinated with SEB toxoid-containing microspheres Infect Immun 63 8 1995 2880 2885
15. D. O'Hagan, and M. Singh Microparticles as vaccine adjuvants and delivery systems Expert Rev. Vaccines 2 2 2003 269 283
16. R.E. Johnson, L.A. Lanaski, V. Gupta, M.J. Griffin, H.T. Gaud, and T.E. Needham Stability of atriopeptin III in poly (lactide-co-glycolide) microparticles J Control Release 17 1991 61
17. T.G. Park, W. Lu, and G. Crotts Importance of in vitro experimental conditions on protein release kinetics, stability and polymer degradation in protein encapsulated poly (d,l-lactic acid-co-glycolic acid) microspheres J Control Release 33 1995 211 219
18. A. Shenderova, T.G. Burke, and S.P. Schwendeman The acidic microclimate in poly(lactide-co-glycolide) microspheres stabilizes camptothecins Pharm Res 16 2 1999 241 248
19. M. van de Weert, W.E. Hennink, and W. Jiskoot Protein instability in poly(lactic-co-glycolic acid) microparticles Pharm Res 17 10 2000 1159 1167
20. J. Kazzaz, J. Neidleman, M. Singh, G. Ott, and D.T. O'Hagan Novel anionic microparticles are a potent adjuvant for the induction of cytotoxic T lymphocytes against recombinant p55 gag from HIV-1 J Control Release 67 2-3 2000 347 356
21. G.R. Otten, M. Schaefer, C. Greer, M. Calderon-Cacia, D. Coit, and J. Kazzaz Induction of broad and potent anti-HIV immune responses in rhesus macaques by priming with a DNA vaccine and boosting with protein-adsorbed PLG microparticles J Virol 77 2003 6087 6092
22. M. Singh, J. Kazzaz, J. Chesko, E. Soenawan, M. Ugozzoli, and M. Giuliani Anionic microparticles are a potent delivery system for recombinant antigens from Neisseria meningitidis serotype B J Pharm Sci 93 2 2004 273 282
23. H. Xie, I. Gursel, B.E. Ivins, M. Singh, D.T. O'Hagan, and J.B. Ulmer CpG oligodeoxynucleotides adsorbed onto polylactide-co-glycolide microparticles improve the immunogenicity and protective activity of the licensed anthrax vaccine Infect Immun 73 2 2005 828 833
24. M. Singh, J. Chesko, J. Kazzaz, M. Ugozzoli, E. Kan, and I. Srivastava Adsorption of a novel recombinant glycoprotein from HIV (Env gp120dV2SF162) to anionic PLG microparticles retains the structural integrity of the protein, while encapsulation in PLG microparticles does not Pharm. Res. 21 12 2004 2148 2152
25. J. Kazzaz, M. Singh, M. Ugozzoli, J. Chesko, E. Soenawan, and D.T. O'Hagan Encapsulation of the adjuvants MPL and RC529 in PLG microparticles enhance their potency J Control Release 2005 [communicated]
26. P. Baldrick, D. Richardson, and A.W. Wheeler Review of l-tyrosine confirming its safe human use as an adjuvant J Appl Toxicol 22 5 2002 333 344
27. H. Aggerbeck, and I. Heron Adjuvanticity of aluminium hydroxide and calcium phosphate in diphtheria-tetanus vaccines - I Vaccine 13 14 1995 1360 1365
28. M. Pizza, V. Scarlato, V. Masignani, M.M. Giuliani, B. Arico, and M. Comanducci Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing Science 287 5459 2000 1816 1820
29. M. Ugozzoli, M. Mariani, G. Del Giudice, E. Soenawan, and D.T. O'Hagan Combinations of protein polysaccharide conjugate vaccines for intranasal immunization J Infect Dis 186 9 2002 1358 1361
30. K. Miyamura, S. Nishio, A. Ito, R. Murata, and R. Kono Micro cell culture method for determination of diphtheria toxin and antitoxin titres using VERO cells. I. Studies on factors affecting the toxin and antitoxin titration J Biol Stand 2 3 1974 189 201
31. T. Heineman, M. Lou, G. Clements-Mann, R. Poland, A. Jacobson, and D. Sakamoto A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant Vaccine 17 1999 2769 2778
32. M. Dupuis, K. Denis-Mize, A. LaBarbara, W. Peters, I.F. Charo, and D.M. McDonald Immunization with the adjuvant MF59 induces macrophage trafficking and apoptosis Eur J Immunol 31 10 2001 2910 2918
33. R.K. Gupta, and G.R. Siber Comparison of adjuvant activities of aluminium phosphate,calcium phosphate and stearyl tyrosine for tetanus toxoid Biologiacls 22 1 1994 53 63